A new molecule discovered by Belgian researcher Nathalie Franchimont’s team was published on Saturday in the journal American Academy of Dermatology.
The molecule, named TYK2, aims to fight psoriasis and other autoimmune diseases.
It has been bought for $4 million by pharmaceutical firm Takeda for commercial use. The news was announced on the sidelines of Belgian Foreign Minister Hadja Lahbib’s visit to Boston, US.
The deal had been announced in a press release by the Japanese firm in early February.
It was developed by a research team led by Belgian professor Nathalie Franchimont, from the Nimbus Therapeutics laboratory located in the state of Massachusetts.
The firm Takeda is also active in Belgium, with a site in Lessines (Hainaut).